Cargando…

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies

Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellomo, Giovanni, Paolini Paoletti, Federico, Chipi, Elena, Petricciuolo, Maya, Simoni, Simone, Tambasco, Nicola, Parnetti, Lucilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760640/
https://www.ncbi.nlm.nih.gov/pubmed/33256252
http://dx.doi.org/10.3390/diagnostics10121015
_version_ 1783627380867203072
author Bellomo, Giovanni
Paolini Paoletti, Federico
Chipi, Elena
Petricciuolo, Maya
Simoni, Simone
Tambasco, Nicola
Parnetti, Lucilla
author_facet Bellomo, Giovanni
Paolini Paoletti, Federico
Chipi, Elena
Petricciuolo, Maya
Simoni, Simone
Tambasco, Nicola
Parnetti, Lucilla
author_sort Bellomo, Giovanni
collection PubMed
description Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study, we investigated the cerebrospinal fluid (CSF) AD biomarkers in different clinical phenotypes of synucleinopathies. CSF Aβ42/Aβ40 ratio, phosphorylated tau and total tau were measured as markers of amyloidosis (A), tauopathy (T) and neurodegeneration (N) respectively, in 98 PD (48 with mild cognitive impairment, PD-MCI; 50 cognitively unimpaired, PD-nMCI), 14 PDD and 15 DLB patients, and 48 neurological controls (CTRL). In our study, CSF AD biomarkers did not significantly differ between CTRL, PD-MCI and PD-nMCI patients. In PD-nMCI and PD-MCI groups, A-/T-/N- profile was the most represented. Prevalence of A+ was similar in PD-nMCI and PD-MCI (10% and 13%, respectively), being higher in PDD (64%) and in DLB (73%). DLB showed the lowest values of Aβ42/Aβ40 ratio. Higher total tau at baseline predicted a worse neuropsychological outcome after one year in PD-MCI. A+/T+, i.e., AD-like CSF profile, was most frequent in the DLB group (40% vs. 29% in PDD).
format Online
Article
Text
id pubmed-7760640
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77606402020-12-26 A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies Bellomo, Giovanni Paolini Paoletti, Federico Chipi, Elena Petricciuolo, Maya Simoni, Simone Tambasco, Nicola Parnetti, Lucilla Diagnostics (Basel) Article Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study, we investigated the cerebrospinal fluid (CSF) AD biomarkers in different clinical phenotypes of synucleinopathies. CSF Aβ42/Aβ40 ratio, phosphorylated tau and total tau were measured as markers of amyloidosis (A), tauopathy (T) and neurodegeneration (N) respectively, in 98 PD (48 with mild cognitive impairment, PD-MCI; 50 cognitively unimpaired, PD-nMCI), 14 PDD and 15 DLB patients, and 48 neurological controls (CTRL). In our study, CSF AD biomarkers did not significantly differ between CTRL, PD-MCI and PD-nMCI patients. In PD-nMCI and PD-MCI groups, A-/T-/N- profile was the most represented. Prevalence of A+ was similar in PD-nMCI and PD-MCI (10% and 13%, respectively), being higher in PDD (64%) and in DLB (73%). DLB showed the lowest values of Aβ42/Aβ40 ratio. Higher total tau at baseline predicted a worse neuropsychological outcome after one year in PD-MCI. A+/T+, i.e., AD-like CSF profile, was most frequent in the DLB group (40% vs. 29% in PDD). MDPI 2020-11-26 /pmc/articles/PMC7760640/ /pubmed/33256252 http://dx.doi.org/10.3390/diagnostics10121015 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bellomo, Giovanni
Paolini Paoletti, Federico
Chipi, Elena
Petricciuolo, Maya
Simoni, Simone
Tambasco, Nicola
Parnetti, Lucilla
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
title A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
title_full A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
title_fullStr A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
title_full_unstemmed A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
title_short A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
title_sort a/t/(n) profile in cerebrospinal fluid of parkinson’s disease with/without cognitive impairment and dementia with lewy bodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760640/
https://www.ncbi.nlm.nih.gov/pubmed/33256252
http://dx.doi.org/10.3390/diagnostics10121015
work_keys_str_mv AT bellomogiovanni atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies
AT paolinipaolettifederico atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies
AT chipielena atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies
AT petricciuolomaya atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies
AT simonisimone atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies
AT tambasconicola atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies
AT parnettilucilla atnprofileincerebrospinalfluidofparkinsonsdiseasewithwithoutcognitiveimpairmentanddementiawithlewybodies